Is The Ban On RU 486 Causing U.S. Research Efforts To Suffer?

Fearing that the publicity surrounding RU 486, the French-made abortion-inducing pill that is now available throughout Europe, would create a demand in the United States, the Food and Drug Administration issued an import ban on the drug in June 1989. Agency officials argued that women in the U.S. might put themselves at risk if they used this non-FDA-approved drug to terminate their own pregnancies. Today, as a result of the ban, RU 486 supplies in the U.S., even for basic research purposes, ar

Written byRobin Eisner
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

For the antiabortion forces, this was a great victory. For abortion rights activists, it represented a defeat, which they are now trying to reverse. In addition, some constituencies outside of the abortion rights battlefield claim to be suffering as a result of the import prohibition. They are patients with cancer and Cushing's disease, among other disorders, whose health, in preliminary clinical studies, has been shown to improve with use of RU 486.

While Congress ponders passing legislation to rescind the import ban (see Commentary, page 12), scientists are debating with supporters of the ban the potential scientific advantages of RU 486, apart from its application as an abortifacient. Yet even in this discussion, the two sides seem inevitably to be drawn back to this inflammatory subject. The following two essays point out the issues of contention between the two factions. In one essay, William Regelson, a physician and professor of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies